DERMATOLOGIC ADVERSE EVENTS WITHIN THE FIRST 60 DAYS OF SORAFENIB TREATMENT ARE ASSOCIATED WITH BETTER OVERALL SURVIVAL (OS) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

被引：0
|
作者：
Reig, M. [1 ]
Rodriguez de Lope, C. [1 ]
Llarch, N. [1 ]
Forner, A. [1 ]
Torres, F. [2 ]
Rios, J. [2 ]
Boix, L. [1 ]
Rimola, J. [3 ]
Darnell, A. [3 ]
Ayuso, C. [3 ]
Bruix, J. [1 ]
机构：
[1] Univ Barcelona, BCLC Grp, Liver Unit, CIBERehd,IDIBAPS,Hosp Clin, Barcelona, Spain
[2] Univ Autonoma Barcelona, IDIBAPS, Hosp Clin Barcelona, Unidad Bioestadist,Fac Med, E-08193 Barcelona, Spain
[3] Univ Barcelona, BCLC Grp, Dept Radiol, CIBERehd,IDIBAPS,Hosp Clin, Barcelona, Spain
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60269-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
267
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [21] Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
    Bruix, Jordi
    Merle, Philippe
    Granito, Alessandro
    Huang, Yi-Hsiang
    Bodoky, Gyorgy
    Yokosuka, Osamu
    Rosmorduc, Olivier
    Breder, Valeriy Vladimirovich
    Gerolami, Rene
    Masi, Gianluca
    Ross, Paul J.
    Qin, Shukui
    Song, Tianqiang
    Bronowicki, Jean-Pierre
    Ollivier-Hourmand, Isabelle
    Kudo, Masatoshi
    Xu, Lei
    Baumhauer, Annette
    Meinhardt, Gerold
    Han, Guohong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
    Jordi, Bruix
    Philippe, Merle
    Alessandro, Granito
    Huang Yi-Hsiang
    Gyorgy, Bodoky
    Osamu, Yokosuka
    Olivier, Rosmorduc
    Valeriy, Breder
    Rene, Gerolami
    Gianluca, Masi
    Ross, Paul J.
    Qin Shukui
    Song Tianqiang
    Jean-Pierre, Bronowicki
    Isabelle, Ollivier-Hourmand
    Masatoshi, Kudo
    Marie-Aude, LeBerre
    Annette, Baumhauer
    Gerold, Meinhardt
    Han Guohong
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo
    Wang, Wei
    Cheng, Jianwen
    Qin, Jiang-Jiang
    Voruganti, Sukesh
    Nag, Subhasree
    Fan, Jia
    Gao, Qiang
    Zhang, Ruiwen
    ONCOTARGET, 2014, 5 (22) : 11604 - 11619
  • [24] Sorafenib Associated Survival in Treatment Naive Versus Treatment Experienced Patients With Advanced Hepatocellular Carcinoma
    Devlin, Paulina
    Cheng, Shanna
    Vyas, Rahul
    Parikh, Neehar D.
    GASTROENTEROLOGY, 2016, 150 (04) : S516 - S516
  • [25] Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
    Antonelli, Giulio
    Gigante, Elia
    Iavarone, Massimo
    Begini, Paola
    Sangiovanni, Angelo
    Iannicelli, Elsa
    Biondetti, Piero
    Pellicelli, Adriano M.
    Miglioresi, Lucia
    Marchetti, Paolo
    Lampertico, Pietro
    Marignani, Massimo
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (07) : 1039 - 1048
  • [26] Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients
    Warit Ruanglertboon
    Michael J. Sorich
    Andrew Rowland
    Ashley M. Hopkins
    International Journal of Clinical Oncology, 2020, 25 : 1672 - 1677
  • [27] Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients
    Ruanglertboon, Warit
    Sorich, Michael J.
    Rowland, Andrew
    Hopkins, Ashley M.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (09) : 1672 - 1677
  • [28] Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
    Schwartz, Gabriel
    Darling, Julianne O.
    Mindo, Malori
    Damicis, Lucia
    TARGETED ONCOLOGY, 2020, 15 (04) : 549 - 565
  • [29] Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
    Gabriel Schwartz
    Julianne O. Darling
    Malori Mindo
    Lucia Damicis
    Targeted Oncology, 2020, 15 : 549 - 565
  • [30] Albi score predicts overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT)
    Finessi, Monica
    Cioffi, Martina
    Grimaldi, Serena
    Fronda, Marco
    Rovera, Guido
    Passera, Roberto
    Carucci, Patrizia
    Gaia, Silvia
    Rolle, Emanuela
    Rizza, Giorgia
    Colli, Fabio
    Saracco, Giorgio Maria
    Romagnoli, Renato
    Calandri, Marco
    Fonio, Paolo
    Morbelli, Silvia Daniela
    Breatta, Andrea Doriguzzi
    RADIOLOGIA MEDICA, 2025, 130 (02): : 271 - 279
12345